Ignite Creation Date:
2024-05-05 @ 11:27 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00046462
Status:
COMPLETED
Last Update Posted:
2011-01-11
First Post:
2002-09-30
Brief Title:
Determine Whether Glycemic Control is Different Between Lantus a 3rd Oral Agent When Failure With Other Treatment
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
Substituting LantusInsulin GlarginerDNAoriginInj for a Thiazolidinedione vs a 3rd Oral Agent as add-on Therapy in Patients Failing a Thiazolidinedione Sulfonylurea or Metformin Combination
Status:
COMPLETED
Status Verified Date:
2011-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purposes of the study is to determine whether blood sugar control is different between Lantus and a third oral anti-diabetic agent when added to patients who fail a thiazolidinedione and sulfonylurea or metformin combination
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None